Field Safety Experience With an Autologous Cancer Vaccine in 41 Horses: A Retrospective Study (2019-2021).

This research article studies the safety of using Autologous Cancer Vaccines (ACVs), a form of active immunotherapy, in horses. The findings suggest that ACVs are generally well-tolerated by horses and may be a viable treatment option for horses with solid tumors.

Overview of the Research

• The research focused on the use of Autologous Cancer Vaccines (ACV), a kind of emerging immunotherapy in veterinary medicine. The purpose of ACV therapy is to stimulate a patient-specific immune response by processing the patient’s own tumor cells and reintroducing them back into the body.
• The study was conducted on horses that had a primary tumor that was either biopsied or surgically removed and received at least one subcutaneous (under the skin) dose of an ACV formulated by Torigen (ACV-T).

Methodology

• The researchers assessed the case database at Torigen to identify suitable subjects for the study.
• A recognized standard formula was applied for qualifying the cases. The horses must have undergone a biopsy or surgical removal of a primary tumor and received at least one dose of the ACV-T.
• The medical records of the qualifying horses were then reviewed for any adverse events (AEs) reported subsequent to the administration of the vaccine.

Results

• The study found that from the 41 horses who received the ACV-T, a total of 252 doses were administered.
• Out of these, there were seven reported adverse events in four horses, representing 1.6% of the total doses that were given.
• All reported adverse events were categorized as mild, suggesting that the ACV therapy was generally well-tolerated by the horses.

Conclusion and Future Implications

• The study indicates that Autologous Cancer Vaccines may serve as a potentially beneficial treatment option for horses with cancer, particularly for those owners concerned about AEs resulting from alternative therapies.
• However, while the findings about the safety of ACV are encouraging, the researchers indicate that further investigation is needed to evaluate the definitive efficacy of this therapy in treating horses with solid tumors.